Adaptive design clinical trials: current status by disease and trial phase in various perspectives-Reference-Cited by-同舟云学术

Adaptive design clinical trials: current status by disease and trial phase in various perspectives

Published:2023 Issue:4 Volume:31 Page:202
ISSN:2289-0882
Container-title:Translational and Clinical Pharmacology
language:en
Short-container-title:Transl Clin Pharmacol

Author:

Lee Hyunjoon¹²^ORCID,Hwang Sejung¹³^ORCID,Jang In-Jin¹^ORCID,Chung Jae-Yong²⁴^ORCID,Oh Jaeseong¹⁵^ORCID

Affiliation:

1. Department of Clinical Pharmacology and Therapeutics, Seoul National University Hospital, Seoul National University College of Medicine, Seoul 03080, Korea.

2. Department of Translational Medicine, Seoul National University College of Medicine, Seoul 03080, Korea.

3. Kidney Research Institute, Seoul National University Medical Research Center, Seoul 03080, Korea.

4. Department of Clinical Pharmacology and Therapeutics, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam 13620, Korea.

5. Department of Pharmacology, Jeju National University College of Medicine, Jeju 63241, Korea.

Funder

Jeju National University

Publisher

XMLink

Subject

Pharmacology (medical)

Link

https://tcpharm.org/pdf/10.12793/tcp.2023.31.e21

Reference21 articles.

1. When to keep it simple – adaptive designs are not always useful

2. Adaptive Design: Results of 2012 Survey on Perception and Use

3. Adaptive designs undertaken in clinical research: a review of registered clinical trials

4. Type I error rate control in adaptive designs for confirmatory clinical trials with treatment selection at interim

5. US Food and Drug Administration. Adaptive designs for clinical trials of drugs and biologics [Internet]. Accessed April 12, 2022. https://www.fda.gov/media/78495/download